Your browser doesn't support javascript.
loading
Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration.
Bai, Jane P F; Earp, Justin C; Florian, Jeffry; Madabushi, Rajanikanth; Strauss, David G; Wang, Yaning; Zhu, Hao.
Affiliation
  • Bai JPF; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Earp JC; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Florian J; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Madabushi R; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Strauss DG; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Wang Y; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Zhu H; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
CPT Pharmacometrics Syst Pharmacol ; 10(12): 1479-1484, 2021 12.
Article in En | MEDLINE | ID: mdl-34734497
ABSTRACT
Quantitative systems pharmacology (QSP) has been proposed as a scientific domain that can enable efficient and informative drug development. During the past several years, there has been a notable increase in the number of regulatory submissions that contain QSP, including Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics License Applications (BLAs) to the US Food and Drug Administration. However, there has been no comprehensive characterization of the nature of these regulatory submissions regarding model details and intended applications. To address this gap, a landscape analysis of all the QSP submissions as of December 2020 was conducted. This report summarizes the (1) yearly trend of submissions, (2) proportion of submissions between INDs and NDAs/BLAs, (3) percentage distribution along the stages of drug development, (4) percentage distribution across various therapeutic areas, and (5) nature of QSP applications. In brief, QSP is increasingly applied to model and simulate both drug effectiveness and safety throughout the drug development process across disease areas.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: United States Food and Drug Administration / Drug Development / Network Pharmacology Type of study: Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2021 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: United States Food and Drug Administration / Drug Development / Network Pharmacology Type of study: Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2021 Type: Article Affiliation country: United States